drugset / Trial / NCT04055818
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Phase 1
Recruiting
20 enrolled
EpiDestiny, Inc.
National Heart, Lung, and Blood Institute (NHLBI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Timeline
- Start
- 2020-01-24
- Primary completion
- 2026-10-30
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 5 mg | Oral |
| Subject | Nicotinamide | Other / unclassified | 1000 mg | Oral |
| Subject | THU | Unknown | 250 mg | Oral |